Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Fate Therapeutics
(NQ:
FATE
)
2.290
+0.220 (+10.63%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
3,910,486
Open
2.100
Bid (Size)
2.280 (416)
Ask (Size)
2.290 (911)
Prev. Close
2.070
Today's Range
2.070 - 2.360
52wk Range
1.960 - 8.830
Shares Outstanding
98,384,456
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence
November 18, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence
November 18, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Performance
YTD
-37.94%
-37.94%
1 Month
-28.21%
-28.21%
3 Month
-39.26%
-39.26%
6 Month
-33.24%
-33.24%
1 Year
-4.18%
-4.18%
More News
Read More
Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
November 12, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Expert Outlook: Fate Therapeutics Through The Eyes Of 9 Analysts
June 17, 2024
Via
Benzinga
Forecasting The Future: 8 Analyst Projections For Fate Therapeutics
May 06, 2024
Via
Benzinga
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting
November 09, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting
November 08, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
November 04, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference
September 12, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
FATE Stock Earnings: Fate Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 13, 2024
Via
InvestorPlace
Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
August 13, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors
July 31, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
July 21, 2024
Via
The Motley Fool
Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
July 16, 2024
Via
Benzinga
UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday
July 16, 2024
Via
Benzinga
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
This Best Buy Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
June 17, 2024
Via
Benzinga
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
June 04, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference
May 29, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Alibaba To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Thursday
May 16, 2024
Via
Benzinga
FATE Stock Earnings: Fate Therapeutics Beats EPS, Beats Revenue for Q1 2024
May 09, 2024
Via
InvestorPlace
Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
May 09, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
May 09, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.